Efficacy and cardiac safety of the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: a systematic review and meta-analysis-Reference-Cited by-同舟云学术

Efficacy and cardiac safety of the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: a systematic review and meta-analysis

Published:2018-09 Issue: Volume:Volume 14 Page:1789-1797
ISSN:1178-203X
Container-title:Therapeutics and Clinical Risk Management
language:en
Short-container-title:TCRM

Author:

Wu Yu-Tuan,Xu Zhou^ORCID,Zhang Ke,Wu Jiu-song,Li Xin,Arshad Bilal,Li Ying-Cun,Wang Zhong-Liang,Li Hong-Yuan,Wu Kai-Nan,Kong Ling-Quan

Publisher

Informa UK Limited

Subject

Chemical Health and Safety,Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics,Safety Research,General Medicine

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Addressing Breast Cancer Disparities in Advancements for Conquering Drug Resistance;Overcoming Breast Cancer Therapy Resistance;2024

2. Dual neoadjuvant blockade plus chemotherapy versus monotherapy for the treatment of women with non-metastatic HER2-positive breast cancer: a systematic review and meta-analysis;Clinical and Translational Oncology;2022-11-22

3. Cardiac Toxicity From Adjuvant Targeting Treatment for Breast Cancer Post-Surgery;Frontiers in Oncology;2022-03-24

4. Neoadjuvant pertuzumab in non‑metastatic HER2‑positive breast tumors: Multicentric study in Peru (NeoHer);Molecular and Clinical Oncology;2022-01-25

5. Recent Progress in Detection of Breast Cancer Biomarkers by Clinical and Imprinting Polymer-Based Sensors;Nanomaterials for Cancer Detection Using Imaging Techniques and Their Clinical Applications;2022